Surface Oncology to Participate in Upcoming Investor Conferences
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced CEO Rob Ross will speak at two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced CEO Rob Ross will speak at two investor conferences. The first is a fireside chat at Cowen's 3rd Annual Virtual Oncology Innovation Summit on June 2, 2022, at 10 a.m. ET, followed by a corporate presentation at the Jefferies Healthcare Conference on June 9, 2022, at 11 a.m. ET. Both events will be available via live audio and archived webcast on the company's website.
Surface Oncology focuses on developing antibody therapies targeting the tumor microenvironment, with a pipeline that includes clinical-stage programs targeting CD39 and IL-27.
Details
News Market Reaction – SURF
The recorded move for SURF in the trading session of this news was -7.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences:
- A fireside chat during Cowen's 3rd Annual Virtual Oncology Innovation Summit on Thursday, June 2, 2022, at 10 a.m. ET.
- A corporate presentation at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 11 a.m. ET.
The live audio and subsequent archived webcast of the fireside chat and corporate presentation will be accessible from the Events & Presentations page of the company's website.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.